UCLA scientists discover mechanism that turns healthy cells into prostate cancer cells

December 02, 2010

A protein that is crucial for regulating the self-renewal of normal prostate stem cells, needed to repair injured cells or restore normal cells killed by hormone withdrawal therapy for cancer, also aids the transformation of healthy cells into prostate cancer cells, researchers at UCLA have found.

The findings, by researchers with the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA, may have important implications for controlling cancer growth and progression.

Done in primary cells and in animal models, the findings from the three-year study appear Dec. 2, 2010 in the early online edition of the peer-reviewed journal Cell Stem Cell.

The protein, called Bmi-1, is often up-regulated in prostate cancer, has been associated with higher grade cancers and is predictive of poor prognosis, according to previous studies. However, its functional roles in prostate stem cell maintenance and prostate cancer have been unclear, said Dr. Owen Witte, who is director of the Broad Stem Cell Research Center, a Howard Hughes Medical Institute investigator and senior author of the study.

A study of loss and gain of function in prostate stem cells indicated that Bmi-1 expression was required for self-renewal activity and maintenance of prostate stem cells with highly proliferative abilities. Loss of Bmi-1 expression blocks the self-renewal activity, protecting prostate cells from developing abnormal growth changes which can lead to cancer.

More importantly, Bmi-1 inhibition slowed the growth of an aggressive form of prostate cancer in animal models, in which the PTEN tumor suppressor gene was removed allowing the cancer to run wild, Witte said.

"We conclude by these results that Bmi-1 is a crucial regulator of self-renewal in adult prostate cells and plays important roles in prostate cancer initiation and progression," Witte said. "It was encouraging to see that inhibiting this protein slows the growth of even a very aggressive prostate cancer, because that could give us new ways to attack this disease."

UCLA stem cell researchers have been studying the mechanisms of prostate stem cells for years on the theory that the mechanism that gives the cells their unique ability to self-renew somehow gets high jacked by cancer cells, allowing the malignant cells to grow and spread. If the mechanism for self-renewal could be understood, researchers could find a way to interrupt it once it is taken over by the cancer cells, Witte said.

Rita Lukacs, a doctoral student in Witte's laboratory and first author of the study, found that Bmi-1 inhibition also stops excessive self-renewal driven by other pathways. This suggests that the Bmi-1 pathway may be dominant to other genetic controls that affect the cancer phenotype.

"Prostate cancer can be initiated by so many different mutations, if we can find a key regulator of self-renewal, we can partially control the growth of the cancer no matter what the mutation is," Lukacs said. "We're attacking the process that allows the cancer cells to grow indefinitely. This provides us an alternate way of attacking the cancer by going to the core mechanism for cancer cell self-renewal and proliferation."

Witte said future work will be centered on searching for methods to control these pathways in human prostate cancer cells.

Prostate cancer is the most frequently diagnosed non-skin cancer and the second most common cause of cancer-related deaths in men. This year alone, more than 277,000 men in the United States will be diagnosed with prostate cancer. Of those, 32,000 men will die from the disease.
-end-
This study was funded by the California Institute for Regenerative Medicine, Howard Hughes Medical Institute, Prostate Cancer Foundation, Ovarian Cancer Research Fund, a Stewart and Lynda Resnick Prostate Cancer Foundation Grant and a Stein/Oppenheimer Clinical Translational Seed Grant.

The stem cell center was launched in 2005 with a UCLA commitment of $20 million over five years. A $20 million gift from the Eli and Edythe Broad Foundation in 2007 resulted in the renaming of the center. With more than 200 members, the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research is committed to a multi-disciplinary, integrated collaboration of scientific, academic and medical disciplines for the purpose of understanding adult and human embryonic stem cells. The center supports innovation, excellence and the highest ethical standards focused on stem cell research with the intent of facilitating basic scientific inquiry directed towards future clinical applications to treat disease. The center is a collaboration of the David Geffen School of Medicine, UCLA's Jonsson Cancer Center, the Henry Samueli School of Engineering and Applied Science and the UCLA College of Letters and Science. To learn more about the center, visit our web site at http://www.stemcell.ucla.edu. To learn more about the center, visit our web site at http://www.stemcell.ucla.edu.

University of California - Los Angeles Health Sciences

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.